Effectiveness of IASTM and Silicone Cupping on Pain, Range of Motion, and Disability in Stage 2 Adhesive Capsulitis Patients in Pakistan: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20261005004

Enrollment

Registered

2026-10-05

Start date

2026-10-11

Completion date

Unknown

Last updated

2026-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHESIVE CAPSULITIS STAGE 2 ADHESIVE CAPSULITIS FROZEN SHOULDER IASTM SILLICON CUPPING PHYSIOTHERAPY

Interventions

Group A: Instrument-Assisted Soft Tissue Mobilization (IASTM) Combined with Conventional Physiotherapy Participants allocated to Group A will receive Instrument-Assisted Soft Tissue Mobilization (IAST

Experimental Other,Experimental Other,Active Comparator Other

IASTM + Standard Physical Therapy,Silicone Cupping + Standard Physical Therapy,Standard Physical Therapy (Control Group)

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with Stage 2 adhesive capsulitis or frozen shoulder. 2. Duration of symptoms between 3 and 6 months. 3. Patients with type 2 diabetes mellitus (HbA1c < 8.5%) and non-diabetic patients. 4. Significant restriction in active and passive shoulder range of motion, particularly external rotation and abduction. 5. Pain score of 4 or above on the Visual Analog Scale (VAS). 6. Willingness to provide informed consent and participate throughout the study period.

Exclusion criteria

Exclusion criteria: 1. History of shoulder trauma, dislocation, or fracture. 2. Previous shoulder surgery or corticosteroid injection in the past 3 months. 3. Diagnosed with rotator cuff tear, calcific tendinitis, or cervical radiculopathy. 4. Patients with rheumatoid arthritis, neurological disorders, or infectious conditions. 5. Skin conditions, open wounds, or contraindications to silicone cupping or IASTM. 6. Uncontrolled diabetes (HbA1c > 8.5%) or other comorbidities that affect healing or participation.

Design outcomes

Primary

Measure	Time frame
Pain BASE LINE ASSESSMENT,AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS VAS(VISUAL ANALOGE SCALE),ROM BASE LINE ASSESSMENT,AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS GONIOMETER,FUNCTIONAL DISABILITY BASE LINE ASSESSMENT,AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS SPADI	—

Secondary

Measure	Time frame
PSYCHO SOCIAL IMAPCT BASE LINE ASSESSMENT,AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS PCS(PAIN CATISTROPHISING SCALE),MUSCLE STRENGTH BASE LINE ASSESSMENT,AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS MMT(MANUAL MUSCLE TESTING),PATIENT SATISFACTION AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS MRPS(MED RISK PATIENT SATISFACTION SCALE),TREATMENT ADHRENCE AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS GRAS (GENERAL REHABILITATION ADHERENCE SCALE)	—

Measure

Time frame

PSYCHO SOCIAL IMAPCT BASE LINE ASSESSMENT,AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS PCS(PAIN CATISTROPHISING SCALE),MUSCLE STRENGTH BASE LINE ASSESSMENT,AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS MMT(MANUAL MUSCLE TESTING),PATIENT SATISFACTION AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS MRPS(MED RISK PATIENT SATISFACTION SCALE),TREATMENT ADHRENCE AFTER 2WEEKS,AND POST TREATMENT AFTER 4 WEEKS GRAS (GENERAL REHABILITATION ADHERENCE SCALE)

—

Countries

Pakistan

Contacts

Public ContactInayat FATIMA

University of sultan zain ul abedin malaysia

physiotherapist.pu@gmail.com03374978410

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Oct 17, 2026